U.S. Physical Therapy Toekomstige groei

Future criteriumcontroles 4/6

U.S. Physical Therapy zal naar verwachting groeien in winst en omzet met respectievelijk 29.4% en 8.9% per jaar. De winst per aandeel zal naar verwachting groeien met 40.1% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 9.2% zijn.

Belangrijke informatie

29.4%

Groei van de winst

40.1%

Groei van de winst per aandeel

Healthcare winstgroei	27.6%
Inkomstengroei	8.9%
Toekomstig rendement op eigen vermogen	9.2%
Dekking van analisten	Good
Laatst bijgewerkt	21 Nov 2024

Recente toekomstige groei-updates

Recent updates

Winst- en omzetgroeiprognoses

DB:UPH - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	778	48	83	87	3
12/31/2025	726	61	70	85	6
12/31/2024	662	50	65	81	6
9/30/2024	639	14	73	82	N/A
6/30/2024	621	16	68	77	N/A
3/31/2024	606	18	66	75	N/A
12/31/2023	599	18	73	82	N/A
9/30/2023	585	24	64	72	N/A
6/30/2023	575	26	62	70	N/A
3/31/2023	564	28	50	58	N/A
12/31/2022	548	29	50	59	N/A
9/30/2022	536	39	48	57	N/A
6/30/2022	522	38	59	68	N/A
3/31/2022	509	37	61	70	N/A
12/31/2021	490	31	68	76	N/A
9/30/2021	477	31	78	86	N/A
6/30/2021	461	30	81	87	N/A
3/31/2021	418	32	95	101	N/A
12/31/2020	418	32	92	100	N/A
9/30/2020	423	30	82	91	N/A
6/30/2020	431	31	72	82	N/A
3/31/2020	473	29	55	65	N/A
12/31/2019	477	31	52	62	N/A
9/30/2019	472	30	56	65	N/A
6/30/2019	468	23	62	71	N/A
3/31/2019	457	18	63	71	N/A
12/31/2018	449	17	66	73	N/A
9/30/2018	442	18	63	70	N/A
6/30/2018	432	22	N/A	65	N/A
3/31/2018	421	21	N/A	58	N/A
12/31/2017	410	22	N/A	57	N/A
9/30/2017	392	20	N/A	53	N/A
6/30/2017	377	20	N/A	42	N/A
3/31/2017	363	21	N/A	51	N/A
12/31/2016	353	21	N/A	51	N/A
9/30/2016	348	20	N/A	48	N/A
6/30/2016	344	21	N/A	49	N/A
3/31/2016	337	21	N/A	49	N/A
12/31/2015	327	21	N/A	38	N/A
9/30/2015	320	21	N/A	45	N/A
6/30/2015	313	20	N/A	43	N/A
3/31/2015	308	20	N/A	45	N/A
12/31/2014	301	19	N/A	41	N/A
9/30/2014	290	19	N/A	45	N/A
6/30/2014	278	18	N/A	45	N/A
3/31/2014	267	18	N/A	44	N/A
12/31/2013	260	18	N/A	45	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei UPH ( 29.4% per jaar) ligt boven de spaarquote ( 1% ).

Winst versus markt: De winst van UPH ( 29.4% per jaar) zal naar verwachting sneller groeien dan de German markt ( 21.1% per jaar).

Hoge groeiwinsten: De winst van UPH zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van UPH ( 8.9% per jaar) zal naar verwachting sneller groeien dan de markt German ( 5.6% per jaar).

Hoge groei-inkomsten: De omzet van UPH ( 8.9% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen UPH zal naar verwachting over 3 jaar laag zijn ( 9.2 %).

U.S. Physical Therapy Toekomstige groei

Future criteriumcontroles 4/6

Belangrijke informatie

Recente toekomstige groei-updates

U.S. Physical Therapy, Inc. Provides Operating Guidance for 2022

U.S. Physical Therapy, Inc. Revises Earnings Guidance for the Year 2021

Recent updates

President & COO recently sold €179k worth of stock

Third quarter dividend of US$0.44 announced

Third quarter 2024 earnings released: EPS: US$0.39 (vs US$0.51 in 3Q 2023)

U.S. Physical Therapy, Inc. Declares Quarterly Dividend, Payable on December 6, 2024

U.S. Physical Therapy, Inc. to Report Q3, 2024 Results on Nov 05, 2024

U.S. Physical Therapy, Inc. Declares Quarterly Dividend, Payable on September 13, 2024

U.S. Physical Therapy, Inc. announced delayed 10-Q filing

U.S. Physical Therapy, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Now 21% undervalued after recent price drop

Chairman & CEO recently sold €196k worth of stock

Chief Operating Officer - East recently sold €242k worth of stock

First quarter dividend of US$0.44 announced

First quarter 2024 earnings released: EPS: US$0.54 (vs US$0.58 in 1Q 2023)

U.S. Physical Therapy, Inc., Annual General Meeting, May 21, 2024

Chief Operating Officer - West recently sold €253k worth of stock

Fourth quarter dividend of US$0.44 announced

New minor risk - Profit margin trend

U.S. Physical Therapy, Inc. Increases Quarterly Dividend, Payable on April 5, 2024

New minor risk - Earnings quality

Full year 2023 earnings released: EPS: US$1.99 (vs US$2.25 in FY 2022)

Now 21% undervalued

U.S. Physical Therapy, Inc. to Report Q4, 2023 Results on Feb 28, 2024

U.S. Physical Therapy, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Now 21% undervalued after recent price drop

Third quarter 2023 earnings released: EPS: US$0.62 (vs US$0.72 in 3Q 2022)

U.S. Physical Therapy, Inc. Declares Quarterly Dividend, Payable on December 8, 2023

U.S. Physical Therapy, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Chief Operating Officer - West recently sold €413k worth of stock

Second quarter 2023 earnings released: EPS: US$0.80 (vs US$0.87 in 2Q 2022)

U.S. Physical Therapy, Inc. Declares Quarterly Dividend, Payable on September 8, 2023

U.S. Physical Therapy, Inc. (NYSE:USPH) acquired a 70% stake in U.S. Physical Therapy, Inc. (NYSE:USPH) for $2.1 million.

U.S. Physical Therapy, Inc. to Report Q2, 2023 Results on Aug 08, 2023

U.S. Physical Therapy, Inc. (NYSE:USPH) acquired 75% interest in Physical therapy practice with four clinics for $3.1 million

U.S. Physical Therapy, Inc. has completed a Follow-on Equity Offering in the amount of $150.00003 million.

U.S. Physical Therapy, Inc. Elects Nancy Ham to the Board of Directors

Upcoming dividend of US$0.43 per share at 1.6% yield

U.S. Physical Therapy Declares Quarterly Dividend, Payable on June 9, 2023

First quarter 2023 earnings released: EPS: US$0.57 (vs US$0.67 in 1Q 2022)

Independent Director recently sold €439k worth of stock

Executive VP recently sold €87k worth of stock

Upcoming dividend of US$0.43 per share at 1.7% yield

Full year 2022 earnings released: EPS: US$2.25 (vs US$2.42 in FY 2021)

U.S. Physical Therapy, Inc. to Report Q4, 2022 Results on Feb 22, 2023

Independent Director recently sold €573k worth of stock

President recently sold €858k worth of stock

U.S. Physical Therapy, Inc. (NYSE:USPH) acquired 80% stake in Thirteen-clinic physical therapy practice from practice’s owners for $25 million.

U.S. Physical Therapy, Inc. (NYSE:USPH) acquired 80% stake in Thirteen-clinic physical therapy practice for $25 million.

Insufficient new directors

Upcoming dividend of US$0.41 per share

Chief Operating Officer - West recently sold €162k worth of stock

Now 23% undervalued after recent price drop

Third quarter 2022 earnings released: EPS: US$0.73 (vs US$0.66 in 3Q 2021)

U.S. Physical Therapy, Inc. Provides Operating Guidance for 2022

U.S. Physical Therapy, Inc. (NYSE : USPH) acquired 60% stake in Fourteen-clinic physical therapy practice for $19.3 million.

U.S. Physical Therapy, Inc. to Report Q3, 2022 Results on Nov 03, 2022

U.S. Physical Therapy, Inc. (NYSE:USPH) acquired 80% stake in Two-Clinic Physical Therapy Practice for $4.2 million.

Director recently bought €78k worth of stock

U.S. Physical Therapy, Inc. (NYSE:USPH) acquired a 70% stake in six-clinic physical therapy practice in West Virginia and Pennsylvania for $3.5 million.

Independent Director recently bought €82k worth of stock

Independent Director recently bought €54k worth of stock

Second quarter 2022 earnings released: EPS: US$0.86 (vs US$0.82 in 2Q 2021)

U.S. Physical Therapy, Inc. Declares Quarterly Dividend, Payable on September 16, 2022

U.S. Physical Therapy, Inc. to Report Q2, 2022 Results on Aug 04, 2022

First quarter 2022 earnings released: EPS: US$0.68 (vs US$0.21 in 1Q 2021)

U.S. Physical Therapy, Inc. Declares Quarterly Dividend, Payable on June 14, 2022

Insufficient new directors

U.S. Physical Therapy, Inc. to Report Q1, 2022 Results on May 05, 2022

U.S. Physical Therapy, Inc., Annual General Meeting, May 17, 2022

U.S. Physical Therapy, Inc. (NYSE:USPH) acquired a 70% stake in Madden and Gilbert Physical Therapy, LP from Chad Madden, Michael Gilbert and others for $11.5 million.

Independent Director recently sold €287k worth of stock

Chief Operating Officer of East recently sold €171k worth of stock

Upcoming dividend of US$0.41 per share

Full year 2021 earnings: Revenues and EPS in line with analyst expectations